Salute e Benessere
Asthma Market to Show Paltry Growth at a CAGR of 1.95% During the Forecast Period (2025-2034) | DelveInsight
Discover the new asthma treatment @
Asthma affects millions worldwide, and its prevalence continues to increase due to urbanization, environmental pollution, changing lifestyles, and higher exposure to allergens. According to DelveInsight analysis, the total number of diagnosed prevalent asthma cases is expected to reach by 2034. Growing patient populations directly drive demand for effective treatments.
Innovations such as smart inhalers, dry powder inhalers, and breath-actuated devices are improving patient adherence, accuracy, and convenience. These technological advancements enhance treatment outcomes and contribute to the expansion of the asthma treatment market.
Severe asthma cases often remain uncontrolled despite conventional treatments, fueling the demand for biologics, such as monoclonal antibodies, that target the IgE, IL-5, and IL-4 pathways. The rising use of precision medicine and personalized therapies is a significant growth driver for the asthma drug market.
Several asthma drugs are in the late-stage pipeline, including which are expected to generate significant revenue by 2034. Other assets by are in the early stages of development.
Current asthma therapies mainly aim to relieve symptoms, reduce airway inflammation, and prevent lung damage, but they do not alter the course of the disease. For patients with severe asthma, treatment extends beyond inhalers to include inhaled corticosteroids combined with long-term controller medications such as bronchodilators, leukotriene receptor antagonists, long-acting muscarinic antagonists, long-acting beta-agonists (LABAs), and sustained-release theophylline. Oral corticosteroids are often introduced when symptoms and flare-ups persist despite these measures.
The US FDA has also approved several biologics for asthma treatment, including . However, asthma care continues to face limitations due to the absence of disease-modifying options. Current therapies primarily manage symptoms but do not reverse airway remodeling or stop disease progression. Non–type 2 asthma remains particularly underserved, and variable effectiveness, high costs, and limited availability constrain the use of biologics. Additional barriers such as poor adherence, inhaler misuse, frequent exacerbations, underdiagnosis, and a lack of tailored pediatric options further impact outcomes—highlighting the urgent need for precision medicine and more accessible, long-term therapeutic solutions.
The expected launch of emerging therapies, such as , and others, is expected to create a positive impact on the market.
, currently in development for severe eosinophilic asthma, is a humanized monoclonal antibody targeting IL-5. Designed as a novel biologic, it combines high binding affinity with long-acting suppression of IL-5, a cytokine that drives eosinophil growth, activation, and survival—making it an established therapeutic target in patients with elevated eosinophil counts. Unlike existing IL-5 inhibitors, depemokimab has an extended half-life and superior affinity, enabling subcutaneous dosing only once every 26 weeks.
In January 2025 , both the and Japan accepted depemokimab for regulatory review for the treatment of asthma with type 2 inflammation. If approved, it would become the first ultra-long-acting biologic offering 6-month dosing. The applications are supported by results from the , which demonstrated significant reductions in exacerbations and hospitalizations when used as an add-on therapy in patients with type 2 inflammatory asthma.
, developed by , is a fixed-dose triple combination delivered via a pressurized metered-dose inhaler (pMDI) using . It contains micronized budesonide (an inhaled corticosteroid), glycopyrronium (a long-acting muscarinic antagonist, LAMA), and formoterol fumarate (a long-acting β2-agonist, LABA). Budesonide provides anti-inflammatory effects, glycopyrronium blocks muscarinic M3 receptors to promote bronchodilation, and formoterol rapidly relaxes bronchial smooth muscle with high selectivity for β2 receptors.
AstraZeneca is conducting multiple Phase III studies to evaluate PT010 in patients with severe asthma who remain uncontrolled despite standard care. The therapy is already marketed as in the US and Japan , and as in Europe , but is currently only approved for the treatment of chronic obstructive pulmonary disease (COPD).
, developed by , is an oral eosinophil maturation inhibitor for the treatment of eosinophilic asthma. Unlike IL-5 biologics, it works by halting eosinophil development before the myelocyte stage, thereby reducing the number of eosinophils. Phase II studies demonstrated dose-related decreases in eosinophils and improvements in lung function (FEV₁), with efficacy comparable to that of IL-5 antibodies. As an oral option, it may provide an alternative to injectables, potentially becoming the first oral therapy for eosinophilic asthma.
The program is in Phase III with three global (2,875 patients). (lung function) is fully enrolled with results expected in Q3 2025, while (focused on exacerbations) are expected to report by late 2026. A launch is targeted for late 2027, with pediatric and Japan -specific trials supporting broader filings.
, developed by , is an oral, reversible covalent inhibitor of , a key regulator in B cells and mast cells involved in immune activation. Using Sanofi's platform, the drug is engineered for selective BTK inhibition with minimal off-target activity, providing rapid and sustained anti-inflammatory effects.
At the , Sanofi reported results from a Phase II proof-of-concept study in patients with moderate to severe asthma who were inadequately controlled on ICS/LABA. Treatment with rilzabrutinib resulted in fewer loss-of-control events and improved symptom management, accompanied by a favorable safety profile. These results support its progression into Phase III testing with a twice-daily oral dosing regimen.
The anticipated launch of these emerging therapies are poised to transform the asthma market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the asthma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the asthma drugs market @
Asthma is the most prevalent chronic respiratory disorder worldwide. It affects the lung airways, which become swollen and constricted in response to different triggers, making it difficult for air to pass through. The interaction between airway inflammation and structural changes leads to airway hyper-responsiveness (AHR), causing irregular and excessive narrowing of the airways.
Asthma is generally categorized as either intermittent or persistent, with persistent asthma further classified into mild, moderate, or severe forms. A combination of genetic predisposition, environmental exposures, psychological factors, and respiratory infections influences the severity of the disease.
The asthma epidemiology section provides insights into the historical and current asthma patient pool and forecasted trends for the leading markets. Among the 7MM, the US accounted for nearly of the total diagnosed prevalent cases of asthma, with around cases in adults in 2024. These cases are expected to increase by 2034.
The asthma treatment market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets [ the United States , the EU4 ( Germany , France , Italy , and Spain ) and the United Kingdom , and Japan ], segmented into:
Download the report to understand who's the best in asthma treatment industry @
ERS Conference 2025 will take place from 27 September to 1 October at RAI Amsterdam, Europaboulevard, 1079 MW Amsterdam. Reach out to us to learn how we can assist in assessing the market landscape for any respiratory indication, considering changes in country-specific treatment guidelines, evolving epidemiology trends, and the influence of new therapies. If you are looking to expand into new geographies but unsure about pricing your drug, schedule a meeting today to transform your business strategy and unlock new growth opportunities.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key asthma companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key severe asthma companies including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key COPD companies including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ARDS companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/asthma-market-to-show-paltry-growth-at-a-cagr-of-1-95-during-the-forecast-period-20252034--delveinsight-302548871.html